New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against mycobacterium tuberculosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Anthony, Karen G ^a   Strych, Ulrich ^b   Yeung, Kacheong R ^a   Shoen, Carolyn S ^c   Perez, Oriana ^a   Krause, Kurt L ^d   Cynamon, Michael H ^c   Aristoff, Paul A ^a   Koski, Raymond A ^a  

^a L2 Diagnostics LLC   (United States)

^b University of Houston   (United States)

^c SYRACUSE VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE RACEMASE; ALANINE DEHYDROGENASE; ANTIINFECTIVE AGENT; ENZYME INHIBITOR;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; CELL DEATH; CHEMISTRY; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; HELA CELL; KINETICS; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; MICROBIOLOGICAL EXAMINATION;

MAMMALIA; MYCOBACTERIUM TUBERCULOSIS;

ALANINE DEHYDROGENASE; ALANINE RACEMASE; ANTI-INFECTIVE AGENTS; CELL DEATH; ENZYME INHIBITORS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SUBSTRATE SPECIFICITY;

EID: 79957558426     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020374     Document Type: Article

References (36)

1. Organization WH (2007) WHO Fact Sheet: Tuberculosis 2007. http://wwwwhoint/mediacentre/factsheets/fs104/en/indexhtml, 2007.
2. Ginsberg AM, (2010) Drugs in development for tuberculosis. Drugs 70: 2201-2214.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
4. Blondal K, (2007) Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis. Bull World Health Organ 85: 387-390; discussion 391-384.
5. Chakrabarti B, Davies PD, (2007) Key issues in multidrug-resistant tuberculosis. Future Microbiol 2: 51-61.
6. Viskum K, Kok-Jensen A, (1997) Multidrug-resistant tuberculosis in Denmark 1993-1995. Int J Tuberc Lung Dis 1: 299-301.
7. Cegielski JP, (2010) Extensively drug-resistant tuberculosis: "there must be some kind of way out of here". Clin Infect Dis 50 (Suppl 3): S195-200.
8. Ginsberg AM, (2010) Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb) 90: 162-167.
9. Laughon BE, (2007) New tuberculosis drugs in development. Curr Top Med Chem 7: 463-473.
10. Ginsberg A, Spigelman M, (2007) Challenges in tuberculosis drug research and development. Nature Medicine 13: 290-294.
11. Neuhaus F, (1967) D-cycloserine and O-carbamyl-D-serine. In: Gottlieb D, Shaw P, editors. Antibiotics, mechanisms of action Heidelbaerg Springer-Verlag.
12. Sassetti CM, Boyd DH, Rubin EJ, (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
13. Milligan DL, Tran SL, Strych U, Cook GM, Krause KL, (2007) The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine. J Bacteriol 189: 8381-8386.
14. Walsh CT, (1989) Enzymes in the D-alanine branch of bacterial cell wall peptidoglycan assembly. J Biol Chem 264: 2393-2396.
15. Lambert MP, Neuhaus FC, (1972) Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. J Bacteriol 110: 978-987.
16. van Heijenoort J, (1994) Biosynthesis of bacterial peptidoglycan unit. In: Ghuysen J, Hakenbeck R, editors. Bacterial Cell Wall Amsterdam Elsevier Medical Press pp. 39-54.
17. LeMagueres P, Im H, Ebalunode J, Strych U, Benedik MJ, et al. (2005) The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site. Biochemistry 44: 1471-1481.
18. Neuhaus F, (1967) D-cycloserine and O-carbamyl-D-serine; In: D G, P S, editors. Heidelbaerg Springer-Verlag.
19. Neuhaus FC, Hammes WP, (1981) Inhibition of cell wall biosynthesis by analogues and alanine. Pharmacol Ther 14: 265-319.
20. Yew WW, Wong CF, Wong PC, Lee J, Chau CH, (1993) Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis 17: 288-289.
21. Kim MG, Strych U, Krause K, Benedik M, Kohn H, (2003) N(2)-substituted D,L-cycloserine derivatives: synthesis and evaluation as alanine racemase inhibitors. J Antibiot (Tokyo) 56: 160-168.
22. Kim MG, Strych U, Krause K, Benedik M, Kohn H, (2003) Evaluation of Amino-substituted Heterocyclic Derivatives as Alanine Racemase Inhibitors. Medicinal Chemistry Research 12: 130-138.
23. Copie V, Faraci WS, Walsh CT, Griffin RG, (1988) Inhibition of alanine racemase by alanine phosphonate: detection of an imine linkage to pyridoxal 5′-phosphate in the enzyme-inhibitor complex by solid-state 15N nuclear magnetic resonance. Biochemistry 27: 4966-4970.
24. Erion MD, Walsh CT, (1987) 1-Aminocyclopropanephosphonate: time-dependent inactivation of 1-aminocyclopropanecarboxylate deaminase and Bacillus stearothermophilus alanine racemase by slow dissociation behavior. Biochemistry 26: 3417-3425.
25. Badet B, Roise D, Walsh CT, (1984) Inactivation of the dadB Salmonella typhimurium alanine racemase by D and L isomers of beta-substituted alanines: kinetics, stoichiometry, active site peptide sequencing, and reaction mechanism. Biochemistry 23: 5188-5194.
26. Fenn TD, Stamper GF, Morollo AA, Ringe D, (2003) A side reaction of alanine racemase: transamination of cycloserine. Biochemistry 42: 5775-5783.
27. Stamper GF, Morollo AA, Ringe D, (1998) Reaction of alanine racemase with 1-aminoethylphosphonic acid forms a stable external aldimine. Biochemistry 37: 10438-10445.
28. Toney MD, (2005) Reaction specificity in pyridoxal phosphate enzymes. Arch Biochem Biophys 433: 279-287.
29. Mustata GI, Soares TA, Briggs JM, (2003) Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers 70: 186-200.
30. Ondrechen MJ, Briggs JM, McCammon JA, (2001) A model for enzyme-substrate interaction in alanine racemase. J Am Chem Soc 123: 2830-2834.
31. Mustata GI, Briggs JM, (2002) A structure-based design approach for the identification of novel inhibitors: application to an alanine racemase. J Comput Aided Mol Des 16: 935-953.
32. Strych U, Penland RL, Jimenez M, Krause KL, Benedik MJ, (2001) Characterization of the alanine racemases from two mycobacteria. FEMS Microbiol Lett 196: 93-98.
33. Esaki N, Walsh CT, (1986) Biosynthetic alanine racemase of Salmonella typhimurium: purification and characterization of the enzyme encoded by the alr gene. Biochemistry 25: 3261-3267.
34. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
35. Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH, (2010) In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother 54: 3478-3480.
36. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ, (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.